A Phase II Evaluation of Cediranib in the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study
Monday, March 30, 2015: 3:02 PM
International Ballroom (Hilton Chicago)
D. P. Bender1, M. Sill2, H. Lankes2, C. J. Darus3, J. Delmore4, J. Rotmensch5, H. J. Gray6, R. S. Mannel7, J. M. Schilder8, K. K. Leslie1, H. D. Reyes1, M. Hunter9, C. K. McCourt10 and M. Samuelson1
1University of Iowa Hospitals and Clinics, Iowa City, IA, 2Gynecologic Oncology Group Statistical and Data Center, Buffalo, NY, 3Maine Medical Partners, Scarborough, ME, 4University of Kansas School of Medicine, Wichita, Wichita, KS, 5Rush University Medical Center, Chicago, IL, 6University of Washington Medical Center, Seattle, WA, 7University of Oklahoma Health Sciences Center, Oklahoma City, OK, 8Indiana University School of Medicine, Indianapolis, IN, 9University of Missouri, Columbia, Columbia, MO, United States, 10Washington University School of Medicine, St Louis, MO
